Last reviewed · How we verify
Capecitabine/Placebo combined with toripalimab
Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.
Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial indication).
At a glance
| Generic name | Capecitabine/Placebo combined with toripalimab |
|---|---|
| Sponsor | XIANG YANQUN |
| Drug class | Fluoropyrimidine chemotherapy combined with PD-1 inhibitor |
| Target | Thymidylate synthase (capecitabine) and PD-1 (toripalimab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is a fluoropyrimidine carbamate that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in rapidly dividing cancer cells. Toripalimab is a humanized monoclonal antibody targeting PD-1 on T cells, blocking the PD-1/PD-L1 interaction to enhance anti-tumor immunity. The combination leverages both direct cytotoxic chemotherapy and immune checkpoint inhibition.
Approved indications
- Gastric or gastroesophageal junction cancer (Phase 3 trial indication)
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Fatigue
- Immune-related adverse events (from toripalimab)
Key clinical trials
- Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors (NA)
- Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer (PHASE3)
- Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: